Thomas P. Ahern
YOU?
Author Swipe
View article: Postdiagnosis Statin Use and Breast Cancer Mortality
Postdiagnosis Statin Use and Breast Cancer Mortality Open
Importance Emerging evidence suggests that cholesterol plays a role in breast cancer (BC) metabolism, raising the possibility that cholesterol-lowering medications, such as statins, may improve BC prognosis. Objective To evaluate the assoc…
View article: Early adipose tissue wasting in a preclinical model of human lung cancer cachexia
Early adipose tissue wasting in a preclinical model of human lung cancer cachexia Open
Cancer cachexia (CC), a syndrome of skeletal muscle and adipose wasting, reduces responsiveness to therapies and increases mortality. There are no approved treatments for CC, which may relate to discordance between preclinical models and h…
View article: Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach
Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach Open
Purpose Tamoxifen is guideline treatment for premenopausal women with estrogen receptor‐positive (ER+) breast cancer. Therapeutic efficacy relies partly on tamoxifen biotransformation by CYP2D6, CYP2C19, and CYP3A4 enzymes. We conducted a …
View article: Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo
Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo Open
If a protective effect of statins on breast cancer recurrence is supported by evidence from the MASTER trial, then the indications for a safe, well-tolerated, and inexpensive treatment can be expanded towards improved clinical outcomes for…
View article: Figure S7 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Figure S7 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Figure S7: Forest plot of IM vs NM, studies from primarily Asian populations only.
View article: Table S2 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Table S2 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Table S2: Search Terms used in systematic review
View article: Figure S8 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Figure S8 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Figure S8: Forest plot of PM or IM vs NM phenotypes.
View article: Figure S5 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Figure S5 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Figure S5: Forest plot of IM vs NM phenotypes.
View article: Figure S2 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Figure S2 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Figure S2: Inverse normal rank percentile of bias adjusted effects.
View article: Figure S3 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Figure S3 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Figure S3: Forest plot of poor vs normal metabolizers, compatible data only.
View article: Data from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Data from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Background:We evaluated the impact of systematic bias due to loss of heterozygosity (LOH) and incomplete phenotyping in studies examining the relationship between CYP2D6 variants and breast cancer recurrence among women treated with tamoxi…
View article: Figure S4 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Figure S4 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Figure S4: Forest plot of PM vs NM metabolizers, including only studies with tabular data.
View article: Figure S1 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Figure S1 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Figure S1: Forest plot of poor vs normal metabolizers.
View article: Table S1 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Table S1 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Table S1: Meta-analysis results stratified by outcome and DNA source.
View article: Figure S6 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
Figure S6 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Supplementary Figure S6: Inverse rank percentile plot.
View article: CLASSIFICATION OF BREAST LYMPHEDEMA IN A RACIALLY DIVERSE COHORT
CLASSIFICATION OF BREAST LYMPHEDEMA IN A RACIALLY DIVERSE COHORT Open
Breast lymphedema is a common sequela of breast conservation that delays healing and reduces quality of life. No rigorous classification system exists for this condition. We explored approaches for classifying breast lymphedema based on br…
View article: <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
<i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis Open
Background: We evaluated the impact of systematic bias due to loss of heterozygosity (LOH) and incomplete phenotyping in studies examining the relationship between CYP2D6 variants and breast cancer recurrence among women treated with tamox…
View article: Early adipose tissue wasting in a novel preclinical model of human lung cancer cachexia
Early adipose tissue wasting in a novel preclinical model of human lung cancer cachexia Open
Summary Cancer cachexia (CC), a syndrome of skeletal muscle and adipose wasting, reduces responsiveness to therapies and increases mortality. There are no approved treatments for CC, which may relate to discordance between pre-clinical mod…
View article: 34P Premenopausal breast cancer and CYP27A1 expression: A cholesterol-associated biomarker
34P Premenopausal breast cancer and CYP27A1 expression: A cholesterol-associated biomarker Open
An important link between hypercholesterolemia and breast cancer (BC) prognosis may be the cholesterol metabolite 27-hydroxycholesterol (27HC) acting as an estrogen receptor (ER) ligand and catalysed by the CYP27A1 enzyme. This study aimed…
View article: 110MO Statin use and early breast cancer survival: A Danish population-based cohort study using an emulated target trial approach
110MO Statin use and early breast cancer survival: A Danish population-based cohort study using an emulated target trial approach Open
Compelling evidence for the role of cholesterol in breast cancer metabolism suggests that cholesterol-lowering medications, such as statins, may improve breast cancer (BC) prognosis. We conducted a target trial to emulate a randomized tria…
View article: The Importance of Making Assumptions in Bias Analysis
The Importance of Making Assumptions in Bias Analysis Open
Quantitative bias analyses allow researchers to adjust for uncontrolled confounding, given specification of certain bias parameters. When researchers are concerned about unknown confounders, plausible values for these bias parameters will …
View article: Long-term Mammography Screening Trends and Predictors of Return to Screening after the COVID-19 Pandemic: Results from a Statewide Registry
Long-term Mammography Screening Trends and Predictors of Return to Screening after the COVID-19 Pandemic: Results from a Statewide Registry Open
Purpose To evaluate long-term trends in mammography screening rates and identify sociodemographic and breast cancer risk characteristics associated with return to screening after the COVID-19 pandemic. Materials and Methods In this retrosp…
View article: Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors
Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors Open
Importance Clinical studies confirm that obesity is a risk factor for recurrence in postmenopausal women with hormone receptor–positive (HR+) breast cancer. Evidence suggests that women with obesity do not obtain similar protection from ar…
View article: 104P Obesity and recurrence in postmenopausal, estrogen-receptor-positive breast cancer patients treated with adjuvant aromatase inhibitors: A Danish population-based cohort study
104P Obesity and recurrence in postmenopausal, estrogen-receptor-positive breast cancer patients treated with adjuvant aromatase inhibitors: A Danish population-based cohort study Open
Clinical studies confirm that obesity is a key risk factor for recurrence in postmenopausal women with estrogen receptor (ER)-positive breast cancer. Concerning evidence suggests that women with obesity do not obtain similar protection fro…
View article: Supplemental Table 1 from Statin Use and Breast Cancer Risk in the Nurses' Health Study
Supplemental Table 1 from Statin Use and Breast Cancer Risk in the Nurses' Health Study Open
Associations between specific statins and invasive breast cancer incidence, in the Nurses' Health Study among new initiators of statins 2004-2012.